{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:10:25Z","timestamp":1684469425271},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1038\/sj.bjc.6602341","type":"journal-article","created":{"date-parts":[[2005,1,18]],"date-time":"2005-01-18T10:21:48Z","timestamp":1106043708000},"page":"217-221","source":"Crossref","is-referenced-by-count":10,"title":["Evolving treatment strategies for myeloma"],"prefix":"10.1038","volume":"92","author":[{"given":"G J","family":"Morgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F E","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,1,18]]},"reference":[{"key":"BF6602341_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349\u2013360","journal-title":"Nat Rev Cancer"},{"key":"BF6602341_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 335: 91\u201397","journal-title":"N Engl J Med"},{"key":"BF6602341_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93: 55\u201365","journal-title":"Blood"},{"key":"BF6602341_CR4","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99: 3163\u20133168","journal-title":"Blood"},{"key":"BF6602341_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1365-2141.2003.03902.x","volume":"120","author":"JD Cavenagh","year":"2003","unstructured":"Cavenagh JD, Oakervee H, UK Myeloma Forum and The BCSH Haematology\/Oncology Task Forces (2003) Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 120: 18\u201326","journal-title":"Br J Haematol"},{"key":"BF6602341_CR6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, on behalf of the Medical Research Council Adult Leukaemia Working Party (2003) High dose therapy improves the outcome of patients with multiple myeloma: The MRC Myeloma VII randomized trial. N Engl J Med 348: 1875\u20131883","journal-title":"N Engl J Med"},{"key":"BF6602341_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1046\/j.1365-2141.2001.02530.x","volume":"112","author":"FE Davies","year":"2001","unstructured":"Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ (2001a) The impact of attaining a minimal disease state following high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112: 814\u2013819","journal-title":"Br J Haematol"},{"key":"BF6602341_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001b) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210\u2013216","journal-title":"Blood"},{"key":"BF6602341_CR9","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131\u20133136","journal-title":"Blood"},{"key":"BF6602341_CR10","unstructured":"Feyler S, Jackson G, Rawstron A, EL-Sherbiny YM, Snowden JA, Johnson RJ (2003) Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. Blood 102, Abstr 2558"},{"key":"BF6602341_CR11","unstructured":"Greipp PR, San Miguel JF, Durie BG, Avet Loiseau H, Fonseca R, Jacobson JL, Rasmussen E, Crowley JJ (2003) A new international staging system (ISS) for multiple myeloma (MM) from the International Myeloma Working Group. Blood 102, Abstr 664"},{"key":"BF6602341_CR12","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943\u20132950","journal-title":"Blood"},{"key":"BF6602341_CR13","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071\u20133076","journal-title":"Cancer Res"},{"key":"BF6602341_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1365-2141.2000.02012.x","volume":"109","author":"JJ Lahuerta","year":"2000","unstructured":"Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, Vazquez L, Garcia-Larana J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, Leon A, Besalduch J, Cabrera R, Miguel JD, Morales A, Garcia-Ruiz JC, Diaz-Mediavilla J, San-Miguel J (2000) Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109: 438\u2013446","journal-title":"Br J Haematol"},{"key":"BF6602341_CR15","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.1073\/pnas.1334037100","volume":"100","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 100: 9946\u20139951","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6602341_CR16","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"CK Lee","year":"2003","unstructured":"Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21: 2732\u20132739","journal-title":"J Clin Oncol"},{"key":"BF6602341_CR17","first-page":"1136","volume":"9","author":"MH Ma","year":"2003","unstructured":"Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumour cells to chemotherapeutic agents. Clin Cancer Res 9: 1136\u20131144","journal-title":"Clin Cancer Res"},{"key":"BF6602341_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0140-6736(92)90004-M","volume":"25","author":"IC MacLennan","year":"1992","unstructured":"MacLennan IC, Chapman C, Dunn J, Kelly K (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 25: 200\u2013205","journal-title":"Lancet"},{"key":"BF6602341_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"ii","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet ii: 822\u2013824","journal-title":"Lancet"},{"key":"BF6602341_CR20","doi-asserted-by":"crossref","unstructured":"Medical Research Council's Working Party on Leukaemia in Adults (1980) Prognostic features in the third MRC myelomatosis trial. Br J Cancer 42: 831\u2013840","DOI":"10.1038\/bjc.1980.330"},{"key":"BF6602341_CR21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377\u20132380","journal-title":"Blood"},{"key":"BF6602341_CR22","unstructured":"Myeloma Trialists Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. J Clin Oncol 16: 3832\u20133842"},{"key":"BF6602341_CR23","doi-asserted-by":"crossref","unstructured":"Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113: 1020\u20131034","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"BF6602341_CR24","unstructured":"Palumbo A, Bertola A, Musto P, Nunzi M, Stefano VD, Callea V, Rotoli B, Petti MC, Caravita T, Lauta VM, Patti C, Bringhen S, Cavallo F, Falco P, Carella AM, Liberati AM, Boccadoro M (2003) Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. Blood 102, Abstr 509"},{"key":"BF6602341_CR25","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20: 4319\u20134323","journal-title":"J Clin Oncol"},{"key":"BF6602341_CR26","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003a) A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 348: 2609\u20132617","journal-title":"N Engl J Med"},{"key":"BF6602341_CR27","unstructured":"Richardson PG, Jagannath S, Schlossman R, Zeldenrust S, Rajkumar SV, Alsina M, Desikan KR, Mitsiades CS, Kelly K, Doss D, McKenney M, Gorelik S, Warren D, Freeman A, Rich R, Knight R, Olesnyckyj M, Patin J, Zeldis J, Dalton W, Anderson KC (2003b) A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 102, Abstr 825"},{"key":"BF6602341_CR28","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063\u20133067","journal-title":"Blood"},{"key":"BF6602341_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","volume":"2","author":"D Samson","year":"1989","unstructured":"Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M et al (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma. Lancet 2: 882\u2013885","journal-title":"Lancet"},{"key":"BF6602341_CR30","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565\u20131571","journal-title":"N Engl J Med"},{"key":"BF6602341_CR31","unstructured":"Streetly M, Jones RW, Knight R, Rassam S, Gillett D, Singer C, Schey S (2003) An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed\/refractory myeloma. Blood 102, Abstr 829"},{"key":"BF6602341_CR32","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-10-3650","volume":"103","author":"S Trudel","year":"2004","unstructured":"Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M, Bergsagel PL (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103: 3521\u20133528","journal-title":"Blood"},{"key":"BF6602341_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16\u201319","journal-title":"J Clin Oncol"},{"key":"BF6602341_CR34","unstructured":"Yang HH, Swift R, Sadler K, Vescio R, Adams J, Schenkein D, Berenson JR (2003) A phase I\/II trial of Velcade and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM). Blood 102, Abstr 826"},{"key":"BF6602341_CR35","unstructured":"Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B, Shaughnessy JD, Anaissie EJ, Thertulien R, Fassas A, Lee CK, Schenkein D, Zeldis JB, Tricot G (2003) VTD egimen comprising Velcade (V)+thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 102, Abstr 830"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602341","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:14:06Z","timestamp":1684412046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["BF6602341"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602341","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}